Convention - partenariat

Bienvenüe call 2021 - Congratulations to Soizic Garaud for her successful application

Dr. Soizic Garaud's will join the LBAI team to lead her postdoctoral project "Immunological variables associated to immune checkpoint inhibitor toxicity in cancer patients".

New study to investigate ianalumab and its mechanism of efficacy in Sjögren's patients

New study to investigate the ianalumab monoclonal antibody and its mechanism of efficacy in Sjögren's patients

Dr. Soizic Garaud joins the team: presentation

Dr. Soizic Garaud is joining the LBAI-UMR1227 as a Postdoctoral Fellow after her project "Immunological variables associated to immune checkpoint inhibitor toxicity in cancer patients" was selected in the framework of the BIENVENÜE programme.

Successful application to MSCA Doctoral Networks 2021 call

LBAI will be involved in a new European project after the successful application of the SIGNATURE proposal to the MSCA Doctoral Networks 2021 call.

The HYPERION platform joins Biogenouest

HYPERION is joining Biogenouest, an interregional network of technology platforms in life and environmental sciences.

New project funded by the Inserm PCSI programme

Dr. Arnaud Uguen has been awarded a grant to lead the project "Combining imaging MAss cytometry with label-free nonlinear and polarized lighT micRoscopIes to decipher the compleX interactions between conjunctive fibers and immune cells in cancer microenvironment: a new approach for biomarker discovery" (MATRIX).

Imaging mass cyctometer Hyperion: a first publication

"High dimensional imaging mass cytometry panel to visualize the tumor immune microenvironment contexture"

Un premier tour de financement bouclé pour KALSIOM...

La start-up brestoise KALSIOM boucle son premier tour de financement de 2 millions € auprès de GO CAPITAL, d'Advent France Biotechnology et de la SATT Ouest Valorisation pour le développement de candidats médicaments "First in Class" en immunothérapie.